Abpro Holdings, Inc.

Abpro Holdings, Inc. is a biotechnology company that develops advanced antibody treatments for patients suffering from severe and life-threatening diseases. The company concentrates on creating new antibodies using its own discovery and engineering platforms. Its primary focus areas are immuno-oncology, ophthalmology, and infectious disease. On November 13, 2024, Atlantic Coastal Acquisition Corp. II (ACAB) completed a merger with Abpro Corporation (Legacy Abpro). As part of this merger, ACAB changed its name to "Abpro Holdings, Inc." and Legacy Abpro became a wholly owned subsidiary of the company. This transaction was accounted for as a reverse recapitalization, with ACAB treated as the acquired company and Legacy Abpro as the acquirer for financial reporting purposes. Operations before the merger are those of Legacy Abpro. Shares of the new Abpro Holdings, Inc. common stock began trading on the Nasdaq Global Market on November 14, 2024. However, due to multiple Nasdaq continued listing non-compliance issues, the company received a delisting notice effective February 23, 2026. Its securities currently trade on the OTC Pink Limited Market, with common shares trading under the ticker symbol ABPO. On March 18, 2026, the company appealed the Nasdaq delisting determination.